Dean J Naisbitt Selected Research

Exanthema (Rash)

1/2023	Characterization of Drug-Specific CD4+ T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions.
1/2021	Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01.
1/2006	Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis.
6/2003	Characterization of drug-specific T cells in lamotrigine hypersensitivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dean J Naisbitt Research Topics

Disease

40	Hypersensitivity (Allergy) 01/2023 - 09/2002
12	Drug Hypersensitivity (Drug Allergy) 01/2023 - 01/2004
9	Chemical and Drug Induced Liver Injury 07/2023 - 01/2015
6	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 06/2010
6	Allergic Contact Dermatitis 10/2015 - 02/2007
5	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2023 - 03/2011
5	Drug-Related Side Effects and Adverse Reactions 01/2022 - 01/2007
4	Exanthema (Rash) 01/2023 - 06/2003
4	Iatrogenic Disease 01/2021 - 02/2013
3	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2023 - 11/2020
2	Gram-Positive Bacterial Infections 01/2024 - 01/2022
2	Drug Hypersensitivity Syndrome 01/2024 - 01/2021
2	Neoplasms (Cancer) 10/2023 - 04/2013
2	Infections 01/2022 - 01/2021
2	Cicatrix (Scar) 01/2022 - 01/2021
2	Contact Dermatitis (Eczema, Contact) 03/2010 - 03/2009
1	Skin Diseases (Skin Disease) 10/2023
1	Cholestasis 01/2023
1	COVID-19 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Eosinophilia 01/2021
1	Agranulocytosis (Granulocytopenia) 11/2020
1	Immediate Hypersensitivity 10/2020
1	Hepatitis C 01/2019
1	Virus Diseases (Viral Diseases) 01/2019
1	Meningism (Meningismus) 01/2017
1	Tuberculosis (Tuberculoses) 01/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2016

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2005
12	AntigensIBA 10/2020 - 09/2002
11	Sulfamethoxazole FDA LinkGeneric 01/2021 - 09/2002
10	Anti-Bacterial Agents (Antibiotics)IBA 01/2024 - 06/2010
8	abacavir (Ziagen)FDA Link 01/2020 - 05/2003
7	Carbamazepine (Tegretol)FDA LinkGeneric 01/2023 - 07/2006
7	LactamsIBA 01/2023 - 06/2012
7	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 05/2013
7	4-phenylenediamine (p-phenylenediamine)FDA Link 10/2015 - 02/2007
6	HLA-B Antigens (HLA-B)IBA 01/2023 - 05/2007
6	HLA-B57 antigenIBA 01/2020 - 11/2012
6	Tuberculin (PPD)IBA 10/2015 - 02/2007
5	HaptensIBA 01/2023 - 09/2011
5	Piperacillin FDA LinkGeneric 01/2018 - 07/2011
4	Anticonvulsants (Antiepileptic Drugs)IBA 01/2023 - 01/2004
4	Floxacillin (Flucloxacillin)IBA 01/2023 - 02/2013
3	Vancomycin FDA LinkGeneric 01/2024 - 01/2021
3	GlycopeptidesIBA 01/2024 - 01/2021
3	Tolvaptan FDA Link 01/2023 - 11/2020
3	Dapsone FDA Link 01/2023 - 01/2019
3	Peptides (Polypeptides)IBA 01/2023 - 01/2020
3	Amoxicillin (Wymox)FDA LinkGeneric 11/2020 - 10/2016
3	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 11/2020 - 10/2016
3	SulfonamidesIBA 08/2014 - 02/2010
2	HLA-A Antigens (HLA-A)IBA 01/2024 - 01/2021
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2020
2	lumacaftorIBA 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2018
2	Penicillins (Penicillin)FDA Link 12/2017 - 09/2011
2	Isoniazid (Ftivazide)FDA LinkGeneric 01/2017 - 01/2015
2	Bandrowski's baseIBA 10/2015 - 04/2008
2	Hair DyesIBA 10/2015 - 02/2007
1	ErbB Receptors (EGF Receptor)IBA 10/2023
1	HLA-C Antigens (HLA-C)IBA 10/2023
1	Ibuprofen (Motrin)FDA LinkGeneric 07/2023
1	Naproxen (Naprosyn)FDA LinkGeneric 07/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/2023
1	Histocompatibility Antigens Class IIIBA 01/2023
1	TeicoplaninIBA 01/2022
1	ivacaftorIBA 01/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	LigandsIBA 01/2021
1	AcidsIBA 01/2021
1	C-Reactive ProteinIBA 01/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021
1	atabecestatIBA 01/2021
1	von Willebrand FactorIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 11/2020
1	Clozapine (Clozaril)FDA LinkGeneric 11/2020
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2019
1	InterferonsIBA 01/2019
1	Ribavirin (Virazole)FDA LinkGeneric 01/2019
1	telaprevirIBA 01/2019
1	Immunoglobulin G (IgG)IBA 12/2017
1	AntibodiesIBA 12/2017
1	Pyrazinamide FDA LinkGeneric 01/2017
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2017
1	Trimethoprim (Proloprim)FDA LinkGeneric 01/2017
1	Ethambutol (Myambutol)FDA LinkGeneric 01/2017
1	Lapatinib (GW572016)FDA Link 12/2016
1	lumiracoxib (prexige)IBA 12/2016
1	Oxypurinol (Oxipurinol)IBA 12/2016
1	ximelagatran (Exanta)IBA 12/2016
1	NucleosidesIBA 04/2014
1	Reverse Transcriptase InhibitorsIBA 04/2014
1	HLA-DRB1*04 antigenIBA 02/2014
1	HLA-A31 antigenIBA 02/2014

Therapy/Procedure

3	Therapeutics 01/2021 - 04/2007
2	Drug Therapy (Chemotherapy) 07/2006 - 01/2004
1	Transplantation 08/2015